According to the announcement of Buchang Pharmaceutical, Shandong Danhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Termination of Drug Registration Application” issued by the State Drug Administration for “Englignet Tablets” and agreed to withdraw the drug registration application and terminate the registration process. Empagliflozin tablets are suitable for the treatment of type 2 diabetes, and sales in the Chinese market increased year by year from 2022 to 2024. The company invested about 15.068 million yuan in R&D expenses on this project. The application was withdrawn because the application data needed to be further improved, and the application will be re-submitted at an optional date after completion. This withdrawal will not have a significant impact on current results, but pharmaceutical products are characterized by high technology, high risk, and high added value, and there are many uncertain risks.

According to the announcement of Buchang Pharmaceutical, Shandong Danhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Termination of Drug Registration Application” issued by the State Drug Administration for “Englignet Tablets” and agreed to withdraw the drug registration application and terminate the registration process. Empagliflozin tablets are suitable for the treatment of type 2 diabetes, and sales in the Chinese market increased year by year from 2022 to 2024. The company invested about 15.068 million yuan in R&D expenses on this project. The application was withdrawn because the application data needed to be further improved, and the application will be re-submitted at an optional date after completion. This withdrawal will not have a significant impact on current results, but pharmaceutical products are characterized by high technology, high risk, and high added value, and there are many uncertain risks.